Composition and Purposes. Vertex and CFFT have established and will continue to participate in a Joint Steering Committee (“JSC”) which shall consist of an equal number of senior management personnel as may be agreed by the parties from time to time. The JSC shall initially have six (6) members. If the JSC chooses to designate a Committee Chair, the Chair will be appointed from among the members of the JSC designated by Vertex. The JSC shall meet semi-annually, or with such other frequency, and at such time and location, as may be established by the Committee, for the following purposes:
Appears in 7 contracts
Samples: Research, Development and Commecialization Agreement (Vertex Pharmaceuticals Inc / Ma), Development and Commecialization Agreement (Royalty Pharma PLC), Research, Development and Commecialization Agreement (Royalty Pharma PLC)
Composition and Purposes. Vertex and CFFT have established and will continue to participate in a Joint Steering Committee (“"JSC”") which shall consist of an equal number of senior management personnel as may be agreed by the parties from time to time. The JSC shall initially have six (6) members. If the JSC chooses to designate a Committee Chair, the Chair will be appointed from among the members of the JSC designated by Vertex. The JSC shall meet semi-annually, or with such other frequency, and at such time and location, as may be established by the Committee, for the following purposes:
Appears in 1 contract
Samples: Development and Commecialization Agreement (Vertex Pharmaceuticals Inc / Ma)
